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In this study, the potency of faropenem (SUN 5555, Sy 
5555, ALP-201 or WY-49605), a new oral penem, 
characterized by a broad spectrum of antimicrobial 
activity [1-6], was explored against a large collection of 
lower respiratory tract pathogens in comparison with 
other oral drugs. Since production of p-lactamases in 
closed-space infections is known to represent a possible 
cause of therapeutic failure [7], the ability of faropenem 
to kill P-lactamase-producing Moraxella catarrhah and 
Haemophilus injuenzae in a dynamic bactericidal model 
was also explored. 
Pathogens were represented by: 503 Streptococcus 
pneumoniae strains, including 29 low-level (MIC 0.12- 
1 mg/L) and high-level (MIC >2 mg/L) penicillin- 
resistant strains; 310 H.  inzuenzae strains (including 
14 p-lactamase producers); and 63 M. catarrhalis strains 
(including 48 P-lactamase producers). All pathogens 
were consecutive (non-duplicate patients) micro- 
organisms isolated from 1993 to 1996 at the Institute of 
Microbiology, Genoa, Italy. 
Faropenem, cefpodoxime and ofloxacin were 
obtained from Roussel Uclaf, Paris, France, while the 
other drugs (arnoxycillin, co-clavulanate, cefpodoxime, 
cefixime, cefuroxime, loracarbef, ofloxacin, cipro- 
floxacin, erythromycin, clarithromycin and azithro- 
mycin) were supplied by their respective manufacturers. 
Sterile stock solutions of the antibiotics were prepared 
from the standard reference powders in accordance 
with the instructions received. 
MICs of faropenem and of the other drugs were 
determined by using the methods suggested by the 
National Committee for Clinical Laboratory Standards 
(NCCLS) [8]. The following ATCC (American Type 
Culture Collection) organisms were included in the 
assays for quahty control: Escherichia coli 25922, Staphylo- 
coccus aureus 29213, Streptococcus pneumoniae 49619, and 
H. injuenzae 49247. 
Time kill experiments were performed with six 
H .  injuenzae strains (three p-lactamase producers) and 
six M. catarrhulis strains (three p-lactamase producers) as 
previously described [9]. 
Towards penicillin-susceptible Streptococcus pneu- 
moniae (Table l ) ,  the new penem was the most active 
drug, followed by amoxycillin, co-clavulanate and 
cefuroxime. 
With respect to intermediately penicdhn-resistant 
pneumococci, faropenem registered the highest activity 
in terms of MIC90 (0.25 mg/L). Against penicillin- 
resistant strains, only amoxycillin and co-clavulanate 
performed as the new agent, while the remaining 
compounds showed lesser activity. 
Considering H. injuenzae and M. catarrhalis isolates 
(Tables 2 and 3), faropenem inhibited all the pathogens 
at a concentration of 2 mg/L, irrespective of their p- 
lactamase production. This level of activity was similar 
to that manifested by comparative antibiotics such 
as co-clavulanate, cefixime, cefuroxime (with the 
exception of p-lactamase-positive H. intuenzae) and 
cefpodoxime. 
Time kill experiments, at 2, 4 and 10 times the 
MICs, carried out on six representative isolates of 
H. injuenzae and M. catarrhalis (four P-lactamase- 
producing and two non-producing strains) revealed 
an excellent bactericidal activity of faropenem. In 
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Table 1 Susceptibility of pneumococci to faropenem and other oral antimicrobial agents 
Drug tested and 
penicillin resistance 
group MIC5o MICw 
(No. ofstrains) 50.03 0.06 0.12 0.25 0.5 1.0 2.0 4.0 8.0 16 >16 (mg/L) (mg/L) 
Cumulative % of strains inhibited at concentration (mg/L) of: 
Faropenem 
s (474) 
1 (16) 
R (13) 
s (474) 
1 (16) 
R (13) 
s (474) 
IU6)  
Amoxycillin 
Co-clawlanate 
R (13) 
Loracarbef 
s (474) 
I(16) 
R (13) 
Cefuroxime 
s (474) 
1 (16) 
R (13) 
s (474) 
1 (16) 
Cefixime 
R (13) 
Cefpodoxime 
s (474) 
I(16) 
R (13) 
s (474) 
I(16) 
R (13) 
s (474) 
I (16) 
R (13) 
s (474) 
1 (16) 
R (13) 
s (474) 
I (16) 
R (13) 
s (474) 
1 (16) 
R (13) 
Ofloxacin 
Ciprofloxacin 
Erythromycin 
Clarithromycin 
Azithromycin 
92 
25 
8 
47 
19 
47 
19 
47 
5 
54 
32 
45 
33 
12 
95 
44 
15 
91 
37 
91 
37 
7 
90 
15 
54 
43 
48 
47 
95 
81 
15 
100 
75 
100 
75 
22 
12 
97 
25 
8 
30 
90 
12 
8 
84 
44 
38 
89 
44 
38 
77 
97 
I00 
46 
87 
46 
87 
46 
43 
19 
8 
98 
56 
8 
48 
95 
56 
8 
5 
89 
50 
38 
89 
50 
38 
85 
100 
54 
100 
46 
100 
46 
54 
31 
8 
100 
69 
15 
90 
98 
56 
23 
10 
11 
12 
8 
89 
50 
38 
89 
50 
38 
88 
50 
31 
100 
100 
100 
87 
44 
15 
94 
23 
91 
6 
100 
75 
30 
48 
44 
50 
44 
54 
89 
50 
38 
89 
56 
38 
89 
50 
31 
I00 
50 
15 
94 
85 
94 
25 
I00 
54 
88 
84 
85 
85 
84 
85 
90 
50 
38 
90 
56 
38 
90 
50 
31 
75 
23 
94 
92 
95 
44 
92 
90 
100 
100 
100 
100 
100 
90 
50 
38 
90 
56 
38 
90 
50 
31 
94 
30 
100 
100 
100 
62 
8 
100 
100 
90 
56 
38 
90 
56 
38 
90 
50 
31 
94 
38 
94 
38 
90 
56 
46 
90 
56 
46 
90 
50 
31 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
50.03 
0.12 
0.5 
0.06 
0.12 
1 
0.06 
0.12 
1 
0.5 
3 
1 
>16 
0.06 
0.25 
3 
1 
0.5 
8 
>16 
50.03 
0.25 
2 
2 
2 
2 
1 
2 
1 
0.12 
0.25 
> 16 
0.12 
0.25 
> 16 
0.12 
0.5 
> 16 
50.03 
0.25 
1 
0.06 
0.5 
1 
0.06 
0.5 
1 
2 
8 
> 16 
0.06 
1 
4 
0.5 
16 
> 16 
0.12 
2 
4 
4 
4 
4 
4 
4 
4 
-I 
1 
>16 
>16 
3 
1 
216 
>16 
2 
>16 
>16 
S, susceptible; I, intermediately resistant; R, resistant. 
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Table 2 Susceptibility of H. influenzae to faropenem and other oral antimicrobial agents 
Drug tested and 
p-lactamase 
group MICso MICm 
(No. ofstrains) 50.03 0.06 0.12 0.25 0.5 1.0 2.0 4.0 8.0 16 >16 (mg/L) (mg/L) 
Cumulative % of strains inhibited at concentration (mg/L) of: 
Faropenem 
pla- (296) 
pla' (14) 
Amoxycillin 
pla- (296) 
pla' (14) 
Co-clavulanate 
Pla- (296) 
pla' (14) 
Loracarbef 
pla- (296) 
@a' (14) 
Cefuroxime 
pla- (296) 
pla' (14) 
Cefvtime 
pla- (296) 
pla+ (14) 
Cefpodoxime 
pla- (296) 
pla' (14) 
Ofloxacin 
pla- (296) 
pla' (14) 
Ciprofloxacin 
pla- (296) 
@a' (14) 
Erythromycin 
pla- (296) 
pla+ (14) 
Clarithromycin 
@la- (296) 
@a' (14) 
Azithromycin 
pla- (296) 
pla' (14) 
47 
29 
48 
36 
80 
71 
95 
93 
0.7 
84 
86 
48 
36 
97 
93 
100 
100 
4 
10 
7 
8 
8 
7 
95 
93 
91 
93 
100 
100 
4 
5 
7 
34 
29 
27 
27 
29 
11 
25 
29 
100 
93 
96 
93 
9 
12 
8 
68 
71 
54 
54 
55 
30 
29 
48 
36 
100 
100 
93 
16 
25 
47 
7 
99 
93 
91 
91 
86 
48 
43 
87 
57 
100 
27 
28 
88 
86 
100 
100 
100 
43 86 
100 
100 
64 78 98 
50 57 86 
100 
86 93 100 
48 91 100 
36 93 100 
48 92 100 
42 93 100 
100 
100 
86 
99 
93 
0.5 
0.5 
0.5 
100 8 
0.5 
0.5 
100 2 
100 2 
1 
1 
0.06 
0.06 
0.12 
0.12 
50.03 
50.03 
50.03 
50.03 
4 
4 
4 
4 
1 
1 
1 
1 
1 
>16 
1 
2 
8 
16 
2 
4 
0.12 
0.12 
0.12 
0.12 
0.06 
0.06 
50.03 
50.03 
4 
4 
4 
4 
2 
2 
pla-, p-lactamase non-producers; pla', P-lactamase producers. 
fact, against al l  strains tested, irrespective of their 
P-lactamase production, a reduction higher than 4 loglo 
CFU/mL (99.99%) of the original inoculum within 
24 h of exposure and no regrowth was noted. In 
comparison with ampicillin, faropenem showed a more 
rapid bactericidal effect against these pathogens, and in 
general the number of survivors at 24 h was lower than 
that registered with ampicillin (Figure 1). 
Regarding the susceptibility patterns of the major 
respiratory pathogens, it may be worth noting that both 
M .  catarrhalis and H .  injuenzae are easily covered by 
faropenem. Of particular interest is the efficacy of 
faropenem against Streptococcus pneumoniae irrespective 
of its susceptibility to penicillin or to other antibiotics. 
If the suggested breakpoint (<2 mg/L) is validated [3], 
in fact, all the microorganisms are inhibited by this 
molecule. This pathogen is responsible for several 
important infections and remains a leading cause of 
morbidity and mortality worldwide, despite the 
availability of several antimicrobial agents that perform 
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Table 3 Susceptibility of M .  crltarrhulis to faropenem and other oral antimicrobial agents 
Drug tested and 
0-lactamase Cumulative O/o of strains inhibited at concentration (mg/L) of: 
P U P  MICsii MICw 
(No. of strains) 50.06 0.12 0.25 0.5 1.0 2.0 4.0 8.0 16 >16 (mg/L) (mg/L) 
Faropenem 
@a+ (48) 
pla- (15) 
Ainoxycillin 
pla+ (48) 
pla- (1 5) 
Co-clavulanate 
pla' (48) 
pla- (15) 
Loracarbef 
pla+ (48) 
pla- (15) 
Cefuroxinie 
pla+ (48) 
pla- (1 5) 
Cefixime 
pla+ (48) 
pla- (15) 
Cefpodoxiine 
pla+ (48) 
pla- (15) 
Ofloxacin 
pla+ (48) 
pla- (15) 
Ciprofloxacin 
61.' (48) 
01,- (1 5) 
Erythromycin 
pla+ (48) 
pla- (15) 
Clarithromycin 
pla+ (48) 
pla- (15) 
Azithromycin 
@a+ (48) 
pla- (15) 
52 
67 
80 
80 
53 
79 
66 
33 
94 
94 
25 
27 
52 
53 
52 
53 
66 
100 
93 
73 
03 
80 
87 
83 
1 I10 
42 
93 
60 
100 
100 
100 
98 
93 
92 
93 
93 
93 
96 
93 
90 
93 
93 
46 
87 
87 
75 
93 
100 
98 
93 
1 on 
100 
100 
1 on 
98 
100 
100 
100 
35 
100 
60 
100 
100 
92 
100 
100 
100 
100 
60 
87 
100 
adequately in vitro [lo, 1 I]. The incidence of penicdlin- 
resistant, multiply-resistant pneumococci is increasing 
worldwide at an alarming rate and represents a worry- 
ing threat [l?]. Although, for non-meningitic infections, 
high-dose penicillin remains clinically effective against 
in vitro resistant strains, this type of treatment is risky 
and may not always be successful [13-151. However, 
many antibiotics are toxic at these levels, and there is, 
in addition, the risk of side effects; also, the threshold 
(level) of resistance of the pathogen can be easily 
50.06 
50.06 
56 92 96 100 4 
50.06 
0.12 
50.06 
81 100 1 
50.06 
100 0.5 
0.12 
50.06 
50.06 
0.25 
0.12 
0.12 
0.12 
50.06 
50.06 
0.12 
0.12 
50.06 
50.06 
50.06 
50.06 
0.25 
0.12 
8 
0.12 
0.25 
0.12 
4 
0.25 
2 
0.5 
0.5 
0.12 
0.5 
0.12 
0.25 
0.13 
50.06 
50.06 
0.12 
0.12 
0.12 
0.12 
0.13 
0.12 
increased, reducing the efficacy of the antibiotic 
prescription. There is an urgent need for oral and 
parenteral p-lactams for the treatment of these in- 
fections [4]. Furthermore, there are currently no 
definite data on which to base treatment of infection 
associated with penicillin-resistant pneumococci. 
Anioxycillin is still regarded as the p-lactam of choice, 
and erythromycin and trimethoprim-sulfamethoxazole 
are currently recommended non-P-lactams; however, 
increased resistance to both these agents is being 
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Figure 1 Time lull kinetics of faropenem (frp) and ampicillin (amp) at 2 times, 4 times and 10 times their respective 
MICs against representative P-lactamase-positive H. iniuenzae (A, B, C),  M.  catarrhah (E, F, G) and P-lactamase-negative 
H. injuenzae (D) and M. catarrhalis (H) strains. 
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reported in many countries [ 161. Faropenem, having an 
easy route of administration and MICs one or two 
dilutions lower than those of amoxycillin for penicillin- 
susceptible and -resistant pneumococci, is of potential 
interest. If human pharmacokinetic and clinical studm 
support these in vitro results, it may be concluded that 
faropenem, a new oral drug. may play a role in the 
treatment of outpatient respiratory tract infections. It 
may also be employed in follow-up treatment after 
parenteral drug administration following hospital dis- 
charge in a number of infections, including aspiration 
pneumonia and osteomyelitis. 
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